Exendin-4 potently decreases ghrelin levels in fasting rats.

Pérez-Tilve D, González-Matías L, Alvarez-Crespo M, Leiras R, Tovar S, Diéguez C, Mallo F, Mallo F

Diabetes1 Jan 2007Cited by 72 (Europe PMC)

PMID17192476DOI10.2337/db05-0996PepBankPUB-17192476

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In fasted rats, exendin‑4 reduced ghrelin levels dose-dependently, with effects lasting up to 8 hours.
In plain wordsIn rats, exendin‑4 lowered ghrelin with dose-dependent effects lasting up to 8 hours.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGhrelin levels
Study
ratn: not reported in source
Fasted rats
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
Dose not stated · central and peripheralAs given in this study (rat).
Measurements
Ghrelin reduction
≤ 74%
fasted rats
Source sentences
Summary
Here, we report that Ex-4 reduces the levels of ghrelin by up to 74% in fasted rats.
1 context sentence(design, population, supporting numbers)
Summary · context
These effects are dose dependent and long lasting (up to 8 h), and they can be detected after both central and peripheral administration of Ex-4.
Report a problemFND-1719247601
02AnimalAnimal study (in vivo)Mechanism
In fasted rats, exendin‑4-induced ghrelin suppression was independent of leptin and insulin levels.
In plain wordsIn rats, exendin‑4's ghrelin effect did not depend on leptin or insulin levels.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableIndependence from leptin and insulin
Study
ratn: not reported in source
Fasted rats
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Moreover, it was independent of the levels of leptin and insulin.
2 context sentences(design, population, supporting numbers)
Summary · context
Here, we report that Ex-4 reduces the levels of ghrelin by up to 74% in fasted rats.
Summary · context
These effects are dose dependent and long lasting (up to 8 h), and they can be detected after both central and peripheral administration of Ex-4.
Report a problemFND-1719247603
03AnimalAnimal study (in vivo)Mechanism
In fasted rats, exendin‑4 suppressed ghrelin, whereas GLP-1(7-36)-NH(2) did not mimic this effect.
In plain wordsIn rats, exendin‑4 lowered ghrelin, whereas GLP-1 did not mimic this effect.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGhrelin suppression versus GLP-1
Study
ratn: not reported in source
Fasted rats
Comparator
GLP-1(7-36)-NH(2)
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Suppression of ghrelin was neither mimicked by GLP-1(7-36)-NH(2) nor blocked by the GLP-1r antagonist Ex-(9-39).
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report that Ex-4 reduces the levels of ghrelin by up to 74% in fasted rats.
Report a problemFND-1719247604

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

04AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism
In fasted rats, GLP-1 receptor antagonism did not block exendin‑4-induced ghrelin suppression.
In plain wordsIn rats, a GLP-1 receptor blocker did not prevent exendin‑4 from lowering ghrelin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGhrelin suppression despite GLP-1 receptor antagonism
Study
ratn: not reported in source
Fasted rats
Comparator
Exendin-4 without GLP-1 receptor antagonist
Outcome group
Appetite and food intake · Endocrine and hormones
Source sentences
Summary
Suppression of ghrelin was neither mimicked by GLP-1(7-36)-NH(2) nor blocked by the GLP-1r antagonist Ex-(9-39).
2 context sentences(design, population, supporting numbers)
Summary · context
Here, we report that Ex-4 reduces the levels of ghrelin by up to 74% in fasted rats.
Summary · context
These effects are dose dependent and long lasting (up to 8 h), and they can be detected after both central and peripheral administration of Ex-4.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1719247602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT01444898

Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

Children's Hospital Los Angelesn = 10Mar 2012 to Dec 2013

Prader-Willi Syndrome

Trial page ClinicalTrials.govUpdated 29 Sept 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.